{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:51:04Z","timestamp":1792270264873,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,10,6]],"date-time":"2012-10-06T00:00:00Z","timestamp":1349481600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s00198-012-2158-8","type":"journal-article","created":{"date-parts":[[2012,10,5]],"date-time":"2012-10-05T05:10:09Z","timestamp":1349413809000},"page":"279-286","source":"Crossref","is-referenced-by-count":33,"title":["Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies"],"prefix":"10.1007","volume":"24","author":[{"given":"K.","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. X.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,6]]},"reference":[{"key":"2158_CR1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jama.2009.50","volume":"301","author":"D Bliuc","year":"2009","unstructured":"Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513\u2013521","journal-title":"JAMA"},{"key":"2158_CR2","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","volume":"353","author":"JR Center","year":"1999","unstructured":"Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878\u2013882","journal-title":"Lancet"},{"key":"2158_CR3","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/ncpendmet0325","volume":"2","author":"JE Mulder","year":"2006","unstructured":"Mulder JE, Kolatkar NS, LeBoff MS (2006) Drug insight: existing and emerging therapies for osteoporosis. Nat Clin Pract Endocrinol Metab 2:670\u2013680","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"2158_CR4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1365-2710.1998.00168.x","volume":"23","author":"JM Macedo","year":"1998","unstructured":"Macedo JM, Macedo CR, Elkis H, De Oliveira IR (1998) Meta-analysis about efficacy of anti-resorptive drugs in post-menopausal osteoporosis. J Clin Pharm Ther 23:345\u2013352","journal-title":"J Clin Pharm Ther"},{"key":"2158_CR5","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5\u00a0years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927\u20132938","journal-title":"JAMA"},{"key":"2158_CR6","doi-asserted-by":"crossref","unstructured":"Arrain Y, Masud T (2011) A current update on osteonecrosis of the jaw and bisphosphonates. Dent Updat 38:672\u2013676, 678","DOI":"10.12968\/denu.2011.38.10.672"},{"key":"2158_CR7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1749-6632.2010.05768.x","volume":"1218","author":"SL Ruggiero","year":"2011","unstructured":"Ruggiero SL (2011) Bisphosphonate-related osteonecrosis of the jaw: an overview. Ann N Y Acad Sci 1218:38\u201346","journal-title":"Ann N Y Acad Sci"},{"key":"2158_CR8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00198-011-1608-z","volume":"23","author":"CW Rhee","year":"2012","unstructured":"Rhee CW, Lee J, Oh S, Choi NK, Park BJ (2012) Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis. Osteoporos Int 23:247\u2013254","journal-title":"Osteoporos Int"},{"key":"2158_CR9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/11584720-000000000-00000","volume":"10","author":"PA Howard","year":"2010","unstructured":"Howard PA, Barnes BJ, Vacek JL, Chen W, Lai SM (2010) Impact of bisphosphonates on the risk of atrial fibrillation. Am J Cardiovasc Drugs 10:359\u2013367","journal-title":"Am J Cardiovasc Drugs"},{"key":"2158_CR10","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","volume":"362","author":"DM Black","year":"2010","unstructured":"Black DM, Kelly MP, Genant HK et al (2010) Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362:1761\u20131771","journal-title":"N Engl J Med"},{"key":"2158_CR11","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","volume":"25","author":"E Shane","year":"2010","unstructured":"Shane E, Burr D, Ebeling PR et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267\u20132294","journal-title":"J Bone Miner Res"},{"key":"2158_CR12","doi-asserted-by":"crossref","first-page":"c4444","DOI":"10.1136\/bmj.c4444","volume":"341","author":"J Green","year":"2010","unstructured":"Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V (2010) Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case\u2013control analysis within a UK primary care cohort. BMJ 341:c4444","journal-title":"BMJ"},{"key":"2158_CR13","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00223-011-9539-4","volume":"89","author":"P Vestergaard","year":"2011","unstructured":"Vestergaard P (2011) Occurrence of gastrointestinal cancer in users of bisphosphonates and other antiresorptive drugs against osteoporosis. Calcif Tissue Int 89:434\u2013441","journal-title":"Calcif Tissue Int"},{"key":"2158_CR14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc0808738","volume":"360","author":"DK Wysowski","year":"2009","unstructured":"Wysowski DK (2009) Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 360:89\u201390","journal-title":"N Engl J Med"},{"key":"2158_CR15","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","volume":"335","author":"PC Groen de","year":"1996","unstructured":"de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK (1996) Esophagitis associated with the use of alendronate. N Engl J Med 335:1016\u20131021","journal-title":"N Engl J Med"},{"key":"2158_CR16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0002-9343(03)00362-0","volume":"115","author":"AN Tosteson","year":"2003","unstructured":"Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209\u2013216","journal-title":"Am J Med"},{"key":"2158_CR17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7326\/0003-4819-148-3-200802050-00198","volume":"148","author":"C MacLean","year":"2008","unstructured":"MacLean C, Newberry S, Maglione M et al (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148:197\u2013213","journal-title":"Ann Intern Med"},{"key":"2158_CR18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jama.2010.1098","volume":"304","author":"CR Cardwell","year":"2010","unstructured":"Cardwell CR, Abnet CC, Cantwell MM, Murray LJ (2010) Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 304:657\u2013663","journal-title":"JAMA"},{"key":"2158_CR19","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097","journal-title":"PLoS Med"},{"key":"2158_CR20","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539\u20131558","journal-title":"Stat Med"},{"key":"2158_CR21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560","journal-title":"BMJ"},{"key":"2158_CR22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188","journal-title":"Control Clin Trials"},{"key":"2158_CR23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1469-1809.1955.tb01348.x","volume":"19","author":"B Woolf","year":"1955","unstructured":"Woolf B (1955) On estimating the relation between blood group and disease. Ann Hum Genet 19:251\u2013253","journal-title":"Ann Hum Genet"},{"key":"2158_CR24","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00019053-200725110-00003","volume":"25","author":"RL Fleurence","year":"2007","unstructured":"Fleurence RL, Iglesias CP, Johnson JM (2007) The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. PharmacoEconomics 25:913\u2013933","journal-title":"PharmacoEconomics"},{"key":"2158_CR25","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1111\/j.1532-5415.2005.53504.x","volume":"53","author":"JT Schousboe","year":"2005","unstructured":"Schousboe JT, Ensrud KE, Nyman JA, Melton LJ 3rd, Kane RL (2005) Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J Am Geriatr Soc 53:1697\u20131704","journal-title":"J Am Geriatr Soc"},{"key":"2158_CR26","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/archinte.166.11.1209","volume":"166","author":"H Liu","year":"2006","unstructured":"Liu H, Michaud K, Nayak S, Karpf DB, Owens DK, Garber AM (2006) The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med 166:1209\u20131217","journal-title":"Arch Intern Med"},{"key":"2158_CR27","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"key":"2158_CR28","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088\u20131101","journal-title":"Biometrics"},{"key":"2158_CR29","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/jbmr.1481","volume":"27","author":"B Abrahamsen","year":"2012","unstructured":"Abrahamsen B, Pazianas M, Eiken P, Russell RG, Eastell R (2012) Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Miner Res 27:679\u2013686","journal-title":"J Bone Miner Res"},{"key":"2158_CR30","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1111\/j.1532-5415.2011.03693.x","volume":"59","author":"YM Chen","year":"2011","unstructured":"Chen YM, Chen DY, Chen LK, Tsai YW, Chang LC, Huang WF, Liu CL, Chen YT, Hsiao FY (2011) Alendronate and risk of esophageal cancer: a nationwide population-based study in Taiwan. J Am Geriatr Soc 59:2379\u20132381","journal-title":"J Am Geriatr Soc"},{"key":"2158_CR31","doi-asserted-by":"crossref","unstructured":"Chiang CH, Huang CC, Chan WL, Huang PH, Chen TJ, Chung CM, Lin SJ, Chen JW, Leu HB (2012) Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: a nationwide study. J Bone Miner Res","DOI":"10.1002\/jbmr.1645"},{"key":"2158_CR32","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1007\/s10620-010-1198-1","volume":"55","author":"DM Nguyen","year":"2010","unstructured":"Nguyen DM, Schwartz J, Richardson P, El-Serag HB (2010) Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett\u2019s esophagus. Dig Dis Sci 55:3404\u20133407","journal-title":"Dig Dis Sci"},{"key":"2158_CR33","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"2158_CR34","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","volume":"49","author":"RG Russell","year":"2011","unstructured":"Russell RG (2011) Bisphosphonates: the first 40\u00a0years. Bone 49:2\u201319","journal-title":"Bone"},{"key":"2158_CR35","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/107327480200900605","volume":"9","author":"CH Poznak Van","year":"2002","unstructured":"Van Poznak CH (2002) The use of bisphosphonates in patients with breast cancer. Cancer Control 9:480\u2013489","journal-title":"Cancer Control"},{"key":"2158_CR36","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1007\/s10495-008-0211-z","volume":"13","author":"L Sewing","year":"2008","unstructured":"Sewing L, Steinberg F, Schmidt H, Goke R (2008) The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis 13:782\u2013789","journal-title":"Apoptosis"},{"key":"2158_CR37","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/bcr412","volume":"4","author":"SG Senaratne","year":"2002","unstructured":"Senaratne SG, Colston KW (2002) Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res 4:18\u201323","journal-title":"Breast Cancer Res"},{"key":"2158_CR38","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-3-642-21892-7_7","volume":"192","author":"M Michailidou","year":"2012","unstructured":"Michailidou M, Holen I (2012) Combinations of bisphosphonates and classical anticancer drugs: a preclinical perspective. Recent Results Cancer Res 192:145\u2013169","journal-title":"Recent Results Cancer Res"},{"key":"2158_CR39","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1200\/JCO.2010.28.2095","volume":"28","author":"RT Chlebowski","year":"2010","unstructured":"Chlebowski RT, Chen Z, Cauley JA et al (2010) Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28:3582\u20133590","journal-title":"J Clin Oncol"},{"key":"2158_CR40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1755-5922.2009.00084.x","volume":"27","author":"NR Robles","year":"2009","unstructured":"Robles NR, Fernandez Carbonero E, Romero B, Sanchez Casado E, Cubero JJ (2009) Long-term antiproteinuric effect of dual renin-angiotensin system blockade. Cardiovasc Ther 27:101\u2013107","journal-title":"Cardiovasc Ther"},{"key":"2158_CR41","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1345\/aph.1Q482","volume":"46","author":"SL Haber","year":"2012","unstructured":"Haber SL, McNatty D (2012) An evaluation of the use of oral bisphosphonates and risk of esophageal cancer. Ann Pharmacother 46:419\u2013423","journal-title":"Ann Pharmacother"},{"key":"2158_CR42","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","volume":"18","author":"JA Cramer","year":"2007","unstructured":"Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023\u20131031","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-012-2158-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-012-2158-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-012-2158-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T08:20:38Z","timestamp":1562228438000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-012-2158-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,6]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["2158"],"URL":"https:\/\/doi.org\/10.1007\/s00198-012-2158-8","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,6]]}}}